Zobrazeno 1 - 10
of 15
pro vyhledávání: '"Laura M Wake"'
Autor:
Laura M. Wake MD, Derek B. Allison MD, Alisha D. Ware MD, Jody E. Hooper MD, Alex S. Baras MD, PhD, Evan M. Bloch MBChB, MS, William Clarke PhD, Kathleen H. Burns MD, PhD, Karen S. Sfanos MS, PhD, Michael J. Borowitz MD, PhD, Charles Steenbergen MD, PhD, Ralph H. Hruban MD, Marissa J. White MD
Publikováno v:
Academic Pathology, Vol 8 (2021)
Pathologists who enter the workforce must have a diverse skill set beyond that of clinical diagnostics alone. Anticipating this need, the Johns Hopkins Pathology Residency Program developed Special Expertise Tracks to enhance training in relevant sub
Externí odkaz:
https://doaj.org/article/a86339f24c504feabc4054c257fe2eee
Publikováno v:
Academic Pathology, Vol 6 (2019)
The following fictional case is intended as a learning tool within the Pathology Competencies for Medical Education (PCME), a set of national standards for teaching pathology. These are divided into three basic competencies: Disease Mechanisms and Pr
Externí odkaz:
https://doaj.org/article/d7290a4c1144446cbf51e23617ee1f63
Autor:
Margaret E Moore, Elizabeth L Courville, Sonam Prakash, Laura E Brown, Rose C Beck, Julie N Qualtieri, Alexa J Siddon, Laura M Wake
Publikováno v:
American Journal of Clinical Pathology.
ObjectivesThis study compares the effectiveness of an interactive e-learning module with a traditional text-based method for teaching peripheral blood smear analysis.MethodsPathology trainees at Accreditation Council for Graduate Medical Education re
Autor:
Laura M. Wake, Amy S. Duffield, Syed Z. Ali, Kathleen H. Burns, Christopher D. Gocke, Milena Vuica-Ross, Christopher J. VandenBussche, Michael J. Borowitz, Nina D. Wagner-Johnston
Publikováno v:
Diagnostic Cytopathology. 48:538-546
BACKGROUND Current clinical practices are shifting towards utilizing less invasive biopsy techniques, including fine needle aspiration (FNA) and needle core biopsies. If a patient has a suspected hematologic malignancy, a portion of the FNA sample is
Autor:
Mohammed Farooqui, Gerald E. Marti, Laura M. Wake, Maryalice Stetler-Stevenson, Adrian Wiestner, Xin Tian, Inhye E. Ahn, Irina Maric
Publikováno v:
Journal of Hematopathology. 12:183-190
Highly effective treatments for chronic lymphocytic leukemia (CLL) have the potential to reduce significant tumor burden to single cells and therefore require sensitive tools to assess for minimal residual disease (MRD) in bone marrow (BM) biopsies.
Autor:
Thomas E. Hughes, Gerald E. Marti, Clare Sun, Ronald P. Taylor, Susan Soto, Adrian Wiestner, Inhye E. Ahn, Irina Maric, Jennifer Lotter, Erika M Gaglione, Constance M. Yuan, Clifton C. Mo, Maryalice Stetler-Stevenson, Laura M Wake, Cydney M. Nichols, Janet Valdez, Christopher Pleyer, Xin Tian, Jeanine Superata, Margaret A. Lindorfer, Mohammed Farooqui, Sarah E. M. Herman, Dennis C Drinkwater, Pia Nierman, Sanjal Desai
Publikováno v:
Leuk Lymphoma
High-risk cytogenetics and minimal residual disease (MRD) after chemoimmunotherapy (CIT) predict unfavorable outcome in chronic lymphocytic leukemia (CLL). This phase 2 study investigated risk-adapted CIT in treatment-naïve CLL (NCT01145209). Patien
Autor:
Alisha D. Ware, Laura M. Wake
Publikováno v:
Blood. 135(23)
Autor:
Laura M. Wake, Caitlin J. Alexander
Publikováno v:
Academic Pathology, Vol 6 (2019)
Academic Pathology
Academic Pathology
The following fictional case is intended as a learning tool within the Pathology Competencies for Medical Education (PCME), a set of national standards for teaching pathology. These are divided into three basic competencies: Disease Mechanisms and Pr
Publikováno v:
Human pathology (New York)
Langerhans Cell Histiocytosis (LCH) and the non-LCH, Erdheim Chester Disease, are rare histiocytic neoplasms with distinctive clinical and immunophenotypic features, but with several overlapping molecular features. LCH is a neoplasm of Langerin-posit
Publikováno v:
Minimal Residual Disease Testing ISBN: 9783319948263
Although many clinical and laboratory features have prognostic significance in acute lymphoblastic leukemia (ALL), the most important one is response to treatment as measured by the presence or absence of minimal residual disease (MRD) after therapy.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::57a3bf1fc38bbc72b321ac353f01f7d1
https://doi.org/10.1007/978-3-319-94827-0_2
https://doi.org/10.1007/978-3-319-94827-0_2